Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Research-Driven Makers Need Enough Capital Strength to Withstand Discontinuation of R&D Projects: Comprehensive Strategy
September 8, 2015
- Can’t Give Timeline for Active Recommendation for HPV Vaccines, Expert Discussions Eyed: Govt
September 8, 2015
- Notification Service for Generic Use Saves 15.8 Billion Yen in Medical Spending in FY2014: Kyokai Kenpo
September 8, 2015
- MHLW Announces Comprehensive Strategy to Beef Up Pharma Industry, Vows to Promote Reward for Innovation
September 7, 2015
- Japan Medical Spending Hits Another Record in FY2014, Year-End Generic Share at 58.4%: MHLW
September 7, 2015
- MEXT Funding Research Project to Propose New Business Models and Financing Methods to Promote Drug Development
September 4, 2015
- PAFSC Committee Recommends Approval for 2 Regenerative Medicine Products
September 4, 2015
- PMDA to Select Products for Sakigake Review; “Probably 5 to 10” Will Be Designated: Official
September 3, 2015
- 5 Companies Find 46 Unreported ADR Cases as a Result of Self-Inspections
September 3, 2015
- Ryukaikon Calls for Elimination of Medical Fee Cut Rule for Low Price Settlement Rates Once Early Price Settlements Are Achieved
September 2, 2015
- Ryukaikon Submits New Proposal to Improve Drug Distribution Environment
September 2, 2015
- AbbVie’s Hep C Drug OK’ed by PAFSC Committee, Setting Stage for Competition with Harvoni
September 1, 2015
- PAFSC First Committee Backs Approval of Glatiramer, Add’l Indication for Xarelto
August 31, 2015
- FY2016 Budget Request to Earmark 151.5 Billion Yen for AMED, with 25.3 Billion Yen for Drug Discovery and Development
August 31, 2015
- METI Seeks 126.9 Billion Yen in FY2016 Budget for Science, Technology Promotion, 21.2 Billion Yen for AMED
August 31, 2015
- MEXT Seeks 5.86 Trillion in FY2016 Budget for “Innovative Drug Discovery for Cancer”
August 31, 2015
- Chuikyo Rep Nakagawa Casts Doubt on 80% Generic Target
August 28, 2015
- MHLW Panel Recommends Creation of Database on Rare Cancers by Type
August 28, 2015
- MHLW Mulls Ordering Pfizer to Improve Biz Operations over ADR Reporting
August 28, 2015
- Panel OKs Medical Subsidy for Harvoni, Monthly Copay Up to 20,000 Yen
August 28, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…